Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Farmers Insurance
UBS
Deloitte
Chinese Patent Office
Daiichi Sankyo
Harvard Business School
Citi
AstraZeneca

Generated: May 26, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021231

« Back to Dashboard

NDA 021231 describes ZOMIG-ZMT, which is a drug marketed by Astrazeneca and is included in one NDA. It is available from two suppliers. Additional details are available on the ZOMIG-ZMT profile page.

The generic ingredient in ZOMIG-ZMT is zolmitriptan. There are twenty drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the zolmitriptan profile page.
Summary for 021231
Tradename:ZOMIG-ZMT
Applicant:Astrazeneca
Ingredient:zolmitriptan
Patents:0
Therapeutic Class:Antimigraine Agents
Formulation / Manufacturing:see details
Pharmacology for NDA: 021231
Suppliers and Packaging for NDA: 021231
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ZOMIG-ZMT zolmitriptan TABLET, ORALLY DISINTEGRATING;ORAL 021231 NDA Global Pharmaceuticals, Division of Impax Laboratories Inc. 0115-0691 N 0115-0691-51
ZOMIG-ZMT zolmitriptan TABLET, ORALLY DISINTEGRATING;ORAL 021231 NDA Global Pharmaceuticals, Division of Impax Laboratories Inc. 0115-0692 N 0115-0692-50

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrength2.5MG
Approval Date:Feb 13, 2001TE:ABRLD:Yes

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, ORALLY DISINTEGRATING;ORALStrength5MG
Approval Date:Sep 17, 2001TE:ABRLD:Yes

Expired US Patents for NDA 021231

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Astrazeneca ZOMIG-ZMT zolmitriptan TABLET, ORALLY DISINTEGRATING;ORAL 021231-001 Feb 13, 2001 ➤ Sign Up ➤ Sign Up
Astrazeneca ZOMIG-ZMT zolmitriptan TABLET, ORALLY DISINTEGRATING;ORAL 021231-002 Sep 17, 2001 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Teva
Deloitte
US Department of Justice
Queensland Health
Farmers Insurance
McKesson
Merck
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.